Pharmacokinetic and toxicological studies of antimony dextran glycoside (RL-712).
1. The absorption, tissue distribution and excretion of antimony dextran glycoside (RL-712) has been studied in normal rodents.2. Some organs in the body, especially liver and spleen, retain large amounts of antimony for considerable periods of time. Excretion of antimony in the urine was low and only about 10-12% of the dose administered was excreted within the first 48 hours.3. Blood levels were maintained for at least 3 days after a single intramuscular dose to rabbits, corresponding to 14 mg Sb/kg body weight.4. Toxicity studies and tests on foetal toxicity in mice and rats, respectively, showed no abnormalities.5. The possible value of RL-712 in the prophylaxis and treatment of leishmaniasis is discussed.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000965:Antimony / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity / Q000652:urine; D003911:Dextrans; D005333:Fetus / Q000187:drug effects; D006027:Glycosides; D007668:Kidney / Q000032:analysis; D007896:Leishmaniasis / Q000188:drug therapy / Q000276:immunology; D008099:Liver / Q000032:analysis / Q000378:metabolism; D051379:Mice; D009206:Myocardium / Q000032:analysis; D011817:Rabbits; D051381:Rats; D013154:Spleen / Q000032:analysis / Q000378:metabolism
D003911:Dextrans; D006027:Glycosides; D000965:Antimony